克唑替尼:全面概况。

Q1 Pharmacology, Toxicology and Pharmaceutics

Profiles of drug substances, excipients, and related methodology Pub Date : 2023-01-01 DOI:10.1016/bs.podrm.2022.11.002

Ahmed A Abdelgalil, Hamad M Alkahtani

{"title":"克唑替尼:全面概况。","authors":"Ahmed A Abdelgalil, Hamad M Alkahtani","doi":"10.1016/bs.podrm.2022.11.002","DOIUrl":null,"url":null,"abstract":"Crizotinib, approved in 2011, was the first approved inhibitor targeting anaplastic lymphoma kinase (ALK) It used for treatment of the patients with metastatic non-small cell lung cancer (NSCLC) that is anaplastic lymphoma kinase (ALK) positive. This chapter provides a complete review of crizotinib including nomenclature, physiochemical properties, methods of preparation, identification techniques and various qualitative and quantitative analytical techniques as well as pharmacology of crizotinib. In addition, the chapter also includes review of several methods for separation of crizotinib using chromatographic techniques.","PeriodicalId":20802,"journal":{"name":"Profiles of drug substances, excipients, and related methodology","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Crizotinib: A comprehensive profile.\",\"authors\":\"Ahmed A Abdelgalil, Hamad M Alkahtani\",\"doi\":\"10.1016/bs.podrm.2022.11.002\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Crizotinib, approved in 2011, was the first approved inhibitor targeting anaplastic lymphoma kinase (ALK) It used for treatment of the patients with metastatic non-small cell lung cancer (NSCLC) that is anaplastic lymphoma kinase (ALK) positive. This chapter provides a complete review of crizotinib including nomenclature, physiochemical properties, methods of preparation, identification techniques and various qualitative and quantitative analytical techniques as well as pharmacology of crizotinib. In addition, the chapter also includes review of several methods for separation of crizotinib using chromatographic techniques.\",\"PeriodicalId\":20802,\"journal\":{\"name\":\"Profiles of drug substances, excipients, and related methodology\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Profiles of drug substances, excipients, and related methodology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1016/bs.podrm.2022.11.002\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"Pharmacology, Toxicology and Pharmaceutics\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Profiles of drug substances, excipients, and related methodology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/bs.podrm.2022.11.002","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}

引用次数: 0

摘要

克唑替尼于2011年获批，是首个获批靶向间变性淋巴瘤激酶(ALK)的抑制剂，用于治疗间变性淋巴瘤激酶(ALK)阳性的转移性非小细胞肺癌(NSCLC)患者。本章对克唑替尼的命名、理化性质、制备方法、鉴定技术、各种定性和定量分析技术以及克唑替尼的药理学等方面进行了全面的综述。此外，本章还回顾了几种使用色谱技术分离克唑替尼的方法。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Crizotinib: A comprehensive profile.

Crizotinib, approved in 2011, was the first approved inhibitor targeting anaplastic lymphoma kinase (ALK) It used for treatment of the patients with metastatic non-small cell lung cancer (NSCLC) that is anaplastic lymphoma kinase (ALK) positive. This chapter provides a complete review of crizotinib including nomenclature, physiochemical properties, methods of preparation, identification techniques and various qualitative and quantitative analytical techniques as well as pharmacology of crizotinib. In addition, the chapter also includes review of several methods for separation of crizotinib using chromatographic techniques.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Profiles of drug substances, excipients, and related methodology Pharmacology, Toxicology and Pharmaceutics-Pharmaceutical Science

CiteScore

13.10

自引率

0.00%

发文量